Cellosaurus DU4475 (CVCL_1183)

Cell line name DU4475
Synonyms DU-4475; Du-4475; DU 4475; Du 4475; Duke University 4475
Accession CVCL_1183
Resource Identification Initiative To cite this cell line use: DU4475 (RRID:CVCL_1183)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: BRAF genetic alteration cell panel (ATCC TCP-1032).
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: ICBP43 breast cancer cell line panel.
Part of: MD Anderson Cell Lines Project.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Doubling time: 2.9 days (PubMed=221108); 90 hours (PubMed=25984343); ~80-100 hours (DSMZ).
Microsatellite instability: Stable (MSS) (Sanger).
Sequence variation: Heterozygous for BRAF p.Val600Glu (ATCC).
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Misspelling: DU-475; In PubMed=12702766.
Misspelling: DU447; In Cosmic 1609476.
Disease Breast carcinoma (NCIt: C4872)
Derived from metastatic site: Skin nodule.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): ATCC; Cosmic-CLP; DSMZ; PubMed=25877200

Markers:
AmelogeninX
CSF1PO9,12
D13S31711,14
D16S53911,12
D18S5114,16
D21S1129,31.2
D3S135814,16
D5S81811 (ATCC; Cosmic-CLP; PubMed=25877200)
6,11 (DSMZ)
D7S8209,10
D8S117910,13
FGA22,25
Penta D13,14
Penta E7,13
TH016,8
TPOX8
vWA17
Web pages http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/DU4475.html
http://lincs.hms.harvard.edu/resources/reagents/icbp43/
http://tcpaportal.org/mclp/
Publications

PubMed=221108
Langlois A.J., Holder W.D. Jr., Iglehart J.D., Nelson-Rees W.A., Wells S.A. Jr., Bolognesi D.P.
Morphological and biochemical properties of a new human breast cancer cell line.
Cancer Res. 39:2604-2613(1979)

PubMed=10862037; DOI=10.1002/1098-2264(200007)28:3<308::AID-GCC9>3.0.CO;2-B
Kytola S., Rummukainen J., Nordgren A., Karhu R., Farnebo F., Isola J., Larsson C.
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Genes Chromosomes Cancer 28:308-317(2000)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

PubMed=28196595; DOI=10.1016/j.ccell.2017.01.005
Li J., Zhao W., Akbani R., Liu W., Ju Z., Ling S., Vellano C.P., Roebuck P., Yu Q., Eterovic A.K., Byers L.A., Davies M.A., Deng W., Gopal Y.N.V., Chen G., von Euw E.M., Slamon D.J., Conklin D., Heymach J.V., Gazdar A.F., Minna J.D., Myers J.N., Lu Y., Mills G.B., Liang H.
Characterization of human cancer cell lines by reverse-phase protein arrays.
Cancer Cell 31:225-239(2017)

Cross-references
Cell line collections ATCC; CRL-7921 - Discontinued
ATCC; HTB-123
DSMZ; ACC-427
Cell line databases/resources CCLE; DU4475_BREAST
CCRID; 3111C0001CCC000342
Cosmic-CLP; 906844
GDSC; 906844
IGRhCellID; DU4475
LINCS_HMS; 50577
LINCS_LDP; LCL-1323
Ontologies CLO; CLO_0002842
EFO; EFO_0002168
Biological sample resources BioSample; SAMN03471772
BioSample; SAMN03473595
Chemistry resources ChEMBL-Cells; CHEMBL3308261
ChEMBL-Targets; CHEMBL2366246
Gene expression databases GEO; GSM217568
GEO; GSM274659
GEO; GSM344345
GEO; GSM344395
GEO; GSM783961
GEO; GSM886989
GEO; GSM888058
GEO; GSM1053707
GEO; GSM1669746
Polymorphism and mutation databases Cosmic; 685863
Cosmic; 871141
Cosmic; 904355
Cosmic; 906844
Cosmic; 921975
Cosmic; 934523
Cosmic; 997915
Cosmic; 1046952
Cosmic; 1047716
Cosmic; 1091340
Cosmic; 1152520
Cosmic; 1289387
Cosmic; 1287936
Cosmic; 1609476
Cosmic; 2164988